DENIED FOR PROFIT: The Political Crime of the US Drug Ransom

The Six-Figure Ransom for the Protocol or Pain

Look, my name doesn’t really matter here. What matters is my story—because it’s basically the entire American healthcare crisis packed into one tiny narrative.

I’ve been living with chronic, debilitating pain since July 1, 1999, when a headache started that literally hasn’t stopped. That’s decades of searching. I finally found a partial answer in a treatment plan I call my “Protocol,” which includes the CGRP inhibitor, Emgality.

This isn’t just a prescription; it’s supposed to be my lifeline. It’s the medicine that, if I can just get approved, would let me get out of bed, actually function as a sister, a dog owner to three amazing rescues, and generally be a productive member of society.

But before I could even take one single dose, I ran smack into two major roadblocks: the shocking price tag and the bureaucratic wall of my insurance company.

The Numbers Don’t Lie – Or Do They?

The manufacturer’s list price for one month’s supply of my preventative medication, Emgality (Galcanezumab), is precisely $909.34 per dose, totaling $9,641.97 annually. My acute migraine medication, Ubrelvy (Ubrogepant), costs approximately $130.71 per pill at retail. If required daily to stop severe spikes, the list price for Ubrelvy alone pushes the cost ceiling to a truly terrifying height—potentially running over $94,000 a year. My actual yearly cost of care for this Protocol—a series of non-negotiable treatments that I have not yet been permitted to start—was suddenly staring down the barrel of six figures.

This financial terror isn’t just happening to me. It’s the very financial shock that bankrupts two out of every three people in America. While I am now in a position where I could, if absolutely forced, pay some of this exorbitant amount out of pocket, that fact only deepens my moral outrage. My ability to survive this ransom does not excuse the system; it simply elevates my responsibility to fight for the millions of Americans who cannot. This cost is not a mistake; it is a meticulously calculated political crime.

Weaponized Denial and the Prior Approval Scam

Let’s be clear: these costs are no accident. They are the direct result of deliberate policy choices designed to protect corporate profits, not us—the patients. When I looked at the $900 price tag for Emgality (a drug that costs literal pennies to manufacture), I wasn’t seeing a normal pharmacy bill. I was looking straight at a legislative failure.

The Myth of Market Pricing

In almost every other developed nation, governments negotiate medication prices directly. But what about the U.S.? We don’t. This single failure is the biggest engine of our entire healthcare financial crisis.

Cutting-edge drugs like Ubrelvy and Emgality are shielded by patents and a market monopoly that simply lets manufacturers name their price. Because there’s no real negotiation, American consumers subsidize pharmaceutical research and massive corporate profits for the rest of the world.

Just consider the data: Lilly’s own website states that they bill my insurance $741.69 for that single dose of Emgality. Travel just north to Canada, and the approximate retail price for that same dose is $444.19 USD. That’s a difference of almost $300.00, representing a staggering 40% delta in price. We see the same policy-engineered chasm with my acute medication. A single dose of Ubrelvy costs $130.71 US at retail, compared to the Canadian retail price of roughly $28.90 CAD—a whopping 78% delta. These price deltas are a direct ransom taken from the US economy that exists solely because Washington allows it.

Then there is the savings card trap. The manufacturer throws you a temporary lifeline, offering a card to drop Emgality’s cost. But that card is only good for 12 months. This isn’t charity. It’s a cynical public relations move that cools down immediate outrage while totally masking the fact that they fully intend to charge you around $10,000 the following year. They intentionally create a terrifying ticking clock, forcing patients to either find a way to pay or face a guaranteed return to debilitating chronic pain. The pharmaceutical industry doesn’t want permanent solutions; they want profitable, recurring crises.

The Fail First Prior Authorization Lie

This is where the insurance company steps in with their own brand of financial warfare: Prior Authorization (PA).

PA is often framed as a “medical necessity check.” That is a total lie. It is primarily a cost-control tool designed to create friction and denial. The insurance company knows that if it makes the process agonizing enough, doctors will give up, and patients will suffer in silence.

They have the power to deny a necessary prescription and force patients onto a brutal “fail first” or “step therapy” regimen. They don’t care that the older drugs may be less effective, or that they aren’t kidney-safe for specific needs. Their sole concern is forcing the patient to exhaust the cheapest, oldest options first. The system literally mandates that the patient must fail before they are even allowed to try to succeed.

For someone like me, who has already cycled through an exhaustive, terrifying list of drugs—experiencing everything from total 24-hour exhaustion to hives and near anaphylactic shock from opioids—this policy is not merely an inconvenience. It feels like medical violence. Requiring a patient to “fail” a long, known list of already failed or dangerous alternatives before being permitted to start a specifically prescribed lifeline proves that the process has nothing to do with medicine and everything to do with money.

Political Paralysis and the Denial of Dignity in the United States

The outrageous bill and the weaponized denial of my medically necessary Protocol are the direct, tragic consequences of policy choices made in Washington—choices that have turned human suffering into a political bargaining chip.

My ability to pay, if necessary, does not mitigate my rage—it magnifies it. My struggle today isn’t solely financial, but moral: the fury that this system forces millions of Americans to choose between their survival and their savings. When I see the insurance company deny my Emgality, I don’t just see a denial of pain relief; I see the exact same corporate calculus that denies life-saving cancer treatments to families who don’t have a safety net. That is the political crime we are exposing.

This is the hypocrisy that fuels the rage. Congress spends weeks arguing over budgets, but they continuously defend a system where they have zero power to negotiate the price of a drug like Emgality. This drug costs the U.S. consumer three times what it costs a patient in Berlin. Drug company lobbyists spend billions to ensure this single, devastating piece of legislation remains unchanged. Ultimately, they guarantee continuous, unchecked profit growth, which is funded directly by the anxiety of every chronic pain patient.

The denial of my prescribed Protocol is not a business decision. It is an act of denial of dignity. It forces a moral choice upon the sick: pay the ransom or continue to suffer. Too often, the pharmaceutical industry and political inaction defend healthcare as a ransom, and they commit a crime against the American family.

The Fight is Personal, The Action is Political

The Inflation Reduction Act (IRA), signed into law in August 2022, was a historic victory—passed with the unifying support of all Democrats in the Senate (51-50, with Vice President Harris breaking the tie). Every Republican, meanwhile, voted against it and continues to pursue attempts to repeal its drug-pricing provisions. This is not a partisan policy debate; it is a clear-cut choice between prioritizing people over profit.

But our fight did not end with the IRA’s passage. Today, the law is under aggressive assault, and the benefits for millions of Americans suffering from chronic pain and illness remain incomplete.

The Two-Front War Against Affordable Drugs

Front 1: The Court Battle (Defending the IRA)

Pharmaceutical giants like Merck, Bristol Myers Squibb (BMS), Johnson & Johnson (J&J), AstraZeneca, Novartis, and Novo Nordisk are actively engaged in lawsuits to block the IRA’s Medicare negotiation provision, claiming it violates their constitutional rights. These are the same companies whose drugs are slated for price cuts in 2026. Their legal action is a desperate attempt to protect billions in revenue, proving that for them, high prices are a corporate policy, not a necessity.

Front 2: The Price Gap (The Non-Negotiators)

Beyond the immediate legal threats, companies like Pfizer and Amgen, though not primary litigants in the current IRA lawsuits, wield influence through their lobbying group PhRMA and maintain exorbitant pricing on critical medications. Meanwhile, millions of patients with chronic illness and pain still battle restrictive Prior Authorization (PA) rules for life-altering drugs like Emgality and Ubrelvy, because the IRA’s negotiation power does not extend to the commercial (private) insurance market.

These companies and their allies stand united against any policy that puts patients before profit. To take the fight directly to the source of the price hikes and legal attacks, click the links above.

The Mandate for Policy Stability

The problem is not the price of Emgality or Ubrelvy. The problem is the architecture of a system that makes a six-figure drug cost a non-negotiable ransom and then empowers an insurance bureaucrat to deny it anyway. This engineered system profits from illness, and it must be dismantled.

This is not a complaint. It is an absolute mandate. They are betting that the millions of Americans silently suffering will remain silent. We cannot let them win that bet. My ability to survive this crisis means I have the moral responsibility to scream on behalf of every family facing a cancer drug denial, every person rationing insulin, and every patient who can no longer afford to push back.

The time for analysis is over. We have seen the anatomy of the sticker shock and the weaponized denial. The six-figure annual ransom for relief is a direct political choice. The only acceptable end to this discussion is to force a system that prioritizes human life and dignity over corporate profits, transforming individual suffering into a powerful, collective mandate for change.

Your Call to Action: Turn Outrage into Power

The architects of this crisis—both corporate and legislative—rely on your silence. Break it.

1. Demand Price Negotiation from Congress

Tell your representatives to fully support and expand the Inflation Reduction Act (IRA) drug price negotiation powers.

Target	Key Congressional Leaders on Drug Reform	Direct Action Link
Defend and Expand Negotiation	Senator Amy Klobuchar (D-MN)	Contact Senator Klobuchar
Defend and Expand Negotiation	Senator Peter Welch (D-VT)	Contact Senator Welch

Action Tip: When using the forms, select “Health Care” or “Prescription Drugs” as the topic. Be brief and explicitly state: “I urge you to defend the IRA’s drug negotiation powers and support the SMART Prices Act to expand price negotiation.”

2. Direct Your Anger to Big Pharma Leadership

These are the companies that manufacture the medications in my Protocol. Hold them accountable for setting the prices that crush American families.

Company (Drug)	CEO Name	Primary Migraine Drug	Best Public Contact Method	Rationale for Contact
Eli Lilly and Company (Emgality)	David A. Ricks	Emgality (CGRP Inhibitor)	Investor Relations: [email protected]	Challenge the $970 price and temporary savings card; demand access now.
AbbVie (Ubrelvy)	Robert A. Michael	Ubrelvy (Gepant)	Media Relations: [email protected]	Stop Prior Authorization (PA) and Step Therapy policies for migraine drugs.

Action Tip: Use the “Contact Us” or general inquiry forms on these pages. Use your personal story (or collect stories from others) to lend moral weight to your complaint about pricing and access policies. Frame your message as a concerned citizen, patient, or advocate. State clearly that the use of Prior Authorization (PA) and Step Therapy is an immoral and cynical policy designed to discourage patients who desperately need these life-changing drugs.

3. Join the Fight for Affordable Drugs

Support the non-profit organizations fighting to lower costs, counter Big Pharma’s legal attacks, and organize patient voices:

• Patients For Affordable Drugs (P4AD): The only national patient organization focused exclusively on lowering drug prices.
• Campaign for Sustainable Rx Pricing (CSRxP): A coalition advocating for market-based reforms to increase competition and accountability.

The suffering is real, and the source of the pain is not just medical. It’s a matter of policy and power. We’ve identified the enemy—the architecture of a system that monetizes chronic illness through high prices and bureaucratic denial. We’ve seen that one political party votes to protect those profits. The other fights tooth and nail to begin dismantling them. Now, it’s our turn. Your individual fight for a life free of pain, for a body that can function as it should, is the fuel for this movement. Turn the outrage of your personal drug ransom amount into a collective voice that Congress and the pharmaceutical industry can no longer afford to ignore. The fight for my Protocol is the fight for every American’s dignity, and it’s a fight we must win, together.